| Identification | Back Directory | [Name]
MBQ-167 | [CAS]
2097938-73-1 | [Synonyms]
MBQ-167
MBQ 167;MBQ167
9-Ethyl-3-(5-phenyl-1H-1,2,3-triazol-1-yl)-9H-carbazole
9H-Carbazole, 9-ethyl-3-(5-phenyl-1H-1,2,3-triazol-1-yl)-
Cyclin dependent kinase,MBQ-167,MBQ167,MBQ 167,Inhibitor,inhibit,CDK,Ras | [Molecular Formula]
C22H18N4 | [MOL File]
2097938-73-1.mol | [Molecular Weight]
338.41 |
| Chemical Properties | Back Directory | [Boiling point ]
531.8±60.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
DMSO: Soluble | [form ]
A solid | [pka]
-0.06±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively. | [in vivo]
MBQ-167-treated mice demonstrate a statistically significant reduction in tumor growth. At sacrifice, 1.0 mg/kg BW of MBQ-167 results in a ~80% reduction in tumor growth, and the 10 mg/kg BW MBQ-167 treatment results in ~95% reduction in tumor growth. Since EHop-016 only exerts ~40% reduction of tumor growth at 10 mg/kg BW, MBQ-167 is 10X more effective than EHop-016. MBQ-167 treated mice demonstrate similar doubling times for both treatments (10 and 11 days)[1]. | [IC 50]
Cdc42: 78 nM (IC50); Ras 1/2/3: 103 nM (IC50) | [References]
[1] Humphries-Bickley T, et al. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol Cancer Ther. 2017 May;16(5):805-818. DOI:10.1158/1535-7163.MCT-16-0442 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|